文献速递肝病

核苷(酸)类似物停药与HBsAg血清学转阴后HBsAg逆转风险无关:全国多中心研究

Discontinuation of nucleos(t)ide analogues is not associated with a higher risk of HBsAg seroreversion after antiviral-induced HBsAg seroclearance: a nationwide multicentre study.
PubMed 文献 · Gut · 2020-03-24

该多中心研究纳入韩国16家医院276例经核苷(酸)类似物(NA)诱导实现HBsAg血清学转阴的慢性乙型肝炎患者,比较停药(131例)与继续治疗(145例)的临床结局。中位随访26.9个月,停药与HBsAg逆转、HBV DNA再检出及HCC发生风险均无显著关联。

要点

  • NA诱导HBsAg转阴后停药不增加HBsAg逆转风险(调整HR=0.65,95%CI 0.16-2.59)。
  • 停药与HBV DNA再检出(HR=0.83)和HCC发生(HR=0.53)风险无关。
  • 停药组1、3、5年HBsAg逆转累积概率分别为0.8%、2.3%、5.0%。

核心结论

  • 在NA诱导实现HBsAg血清学转阴的患者中,停用NA与继续治疗相比,HBsAg逆转、血清HBV DNA再检出及HCC发生风险均无显著升高。

研究设计与样本

  • 多中心研究,纳入韩国16家医院276例经NA诱导实现HBsAg血清学转阴的慢性乙型肝炎患者。
  • 131例(47.5%)在HBsAg转阴后6个月内停用NA(停药组),145例(52.5%)继续NA治疗(继续组)。
  • 主要终点为HBsAg逆转,次要终点包括血清HBV DNA再检出和HCC发生。

主要发现

  • 中位随访26.9个月(IQR 12.2-49.2个月)期间,10例(3.6%)发生HBsAg逆转,6例(2.2%)HBV DNA再检出,8例(2.9%)发生HCC。
  • 停药与HBsAg逆转无关:单因素分析HR=0.45(95%CI 0.12-1.76,log-rank p=0.24),多因素分析调整HR=0.65(95%CI 0.16-2.59,p=0.54)。
  • 停药组1、3、5年HBsAg逆转累积概率分别为0.8%、2.3%、5.0%;继续组分别为1.5%、6.3%、8.4%。
  • 停药与HBV DNA再检出(HR=0.83,95%CI 0.16-4.16,log-rank p=0.82)及HCC发生(HR=0.53,95%CI 0.12-2.23,log-rank p=0.38)风险无关。

临床怎么用

  • 对于NA诱导实现HBsAg血清学转阴的慢性乙型肝炎患者,可考虑停用NA,但需结合个体情况并密切随访HBsAg和HBV DNA。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Direct comparison of the clinical outcomes between nucleos(t)ide analogue (NA) discontinuation versus NA continuation has not been performed in patients with chronic hepatitis B who achieved HBsAg-seroclearance. Whether NA discontinuation was as safe as NA continuation after NA-induced surface antigen of HBV (HBsAg) seroclearance was investigated in the present study. DESIGNS: This multicentre study included 276 patients from 16 hospitals in Korea who achieved NA-induced HBsAg seroclearance: 131 (47.5%) discontinued NA treatment within 6 months after HBsAg seroclearance (NA discontinuation group) and 145 (52.5%) continued NA treatment (NA continuation group). Primary endpoint was HBsAg reversion and secondary endpoints included serum HBV DNA redetection and development of hepatocellular carcinoma (HCC). RESULTS: During follow-up (median=26.9 months, IQR=12.2-49.2 months), 10 patients (3.6%) experienced HBsAg reversion, 6 (2.2%) showed HBV DNA redetection and 8 (2.9%) developed HCC. Compared with NA continuation, NA discontinuation was not associated with HBsAg reversion in both univariable (HR=0.45, 95% CI=0.12 to 1.76, log-rank p=0.24) and multivariable analyses (adjusted HR=0.65, 95% CI=0.16 to 2.59, p=0.54). The cumulative probabilities of HBsAg reversion at 1, 3 and 5 years were 0.8%, 2.3% and 5.0% in the NA discontinuation group, and 1.5%, 6.3% and 8.4% in the NA continuation group, respectively. NA discontinuation was not associated with higher risk of either HBV redetection (HR=0.83, 95% CI=0.16 to 4.16, log-rank p=0.82) or HCC development (HR=0.53, 95% CI=0.12 to 2.23, log-rank p=0.38). CONCLUSION: The discontinuation of NA was not associated with a higher risk of either HBsAg reversion, serum HBV DNA redetection or HCC development compared with NA continuation among patients who achieved HBsAg seroclearance with NA.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Kim MA, Kim SU, Sinn DH, et al. Discontinuation of nucleos(t)ide analogues is not associated with a higher risk of HBsAg seroreversion after antiviral-induced HBsAg seroclearance: a nationwide multicentre study. Gut. 2020. PMID: 32209606. doi:10.1136/gutjnl-2019-320015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。